Ondansetron

[1]Brown AM, et al. Ion permeation and conduction in a human recombinant 5-HT3 receptor subunit (h5-HT3A) . J Physiol. 1998 Mar 15;507 (Pt 3) :653-65.|[2]Barann M, et al. Recombinant human 5-HT3A receptors in outside-out patches of HEK 293 cells: basic properties and barbiturate effects. Naunyn Schmiedebergs Arch Pharmacol. 2000 Sep;362 (3) :255-65.|[3]Wildeboer KM, et al. Ondansetron results in improved auditory gating in DBA/2 mice through a cholinergic mechanism. Brain Res. 2009 Dec 1;1300:41-50.|[4]Khedhaier A, et al. Circadian rhythms in toxic effects of the serotonin antagonist ondansetron in mice. Chronobiol Int. 2003 Nov;20 (6) :1103-16.|[5]Umathe SN, et al. The 5-HT3 receptor antagonist, ondansetron, blocks the development and expression of ethanol-induced locomotor sensitization in mice. Behav Pharmacol. 2009 Feb;20 (1) :78-83.|[6]Doggrell SA, et al. Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia. Expert Opin Drug Saf. 2013 May;12 (3) :421-31.|[7]Xin Wang, et al. Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung Cancer. Cell Biochem Biophys. 2015 Jun;72 (2) :471-3.|[8]Azadeh Motavallian-Naeini, et al. Anti-inflammatory effect of ondansetron through 5-HT3 receptors on TNBS-induced colitis in rat. EXCLI J2012 Feb 22:11:30-44. eCollection 2012.|[9]허원석. Effects of ondansetron on the activity of glutamate transporter type 3 and the modulation mechanism[D]. 서울대학교 대학원, 2014.

Adv Sci (Weinh) . 2025 Apr 7:e2503739.|Biochem Biophys Res Commun. 2025 Oct 30:786:152756.|Front Pharmacol. 2024 Aug 21:15:1443169.|J Ethnopharmacol. 2024 Apr 6:323:117703.|J Radiat Res Appl Sci. 2023 Dec, 16 (4), 100682.|Prog Neuropsychopharmacol Biol Psychiatry. 2023 Mar 2:122:110689.|SSRN. 2023 Srep 5.|Eur J Pharm Sci. 2023 Aug 1:187:106475.|Int J Pharm. 2015 Dec 30;496 (1) :33-41.|Patent. US20170319486A1.